These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 32877516

  • 1. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N, Oleshko O, Werwitzke S, Solecka-Witulska B, Kannicht C, Tiede A.
    Blood; 2021 Feb 25; 137(8):1072-1081. PubMed ID: 32877516
    [Abstract] [Full Text] [Related]

  • 2. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
    Vargas Christensen I, Loftager M, Rode F, Mørck Nielsen H, Kreilgaard M, Larsen MS.
    J Thromb Haemost; 2019 Jun 25; 17(6):964-974. PubMed ID: 30924607
    [Abstract] [Full Text] [Related]

  • 3. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun 25; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F, Almholt K, Petersen M, Kreilgaard M, Kjalke M, Karpf DM, Groth AV, Johansen PB, Larsen LF, Loftager M, Haaning J.
    J Thromb Haemost; 2018 Jun 25; 16(6):1141-1152. PubMed ID: 29582559
    [Abstract] [Full Text] [Related]

  • 6. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N, Merlen C, Bonnefoy A, St-Louis J, Rivard GE.
    Haemophilia; 2016 May 25; 22(3):e177-83. PubMed ID: 26988074
    [Abstract] [Full Text] [Related]

  • 7. Progress in the treatment of bleeding disorders.
    Bergman GE.
    Thromb Res; 2011 Jan 25; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
    Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR.
    J Thromb Haemost; 2012 Nov 25; 10(11):2328-37. PubMed ID: 22908929
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C, Oldenburg J, Ettingshausen CE, Tiede A, Khair K, Négrier C, Klamroth R.
    Haemophilia; 2015 Jan 25; 21 Suppl 1():1-12. PubMed ID: 25472812
    [Abstract] [Full Text] [Related]

  • 12. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G, Ito J, Mercer R, Baldwin WH, Cox C, Parker ET, Healey JF, Lollar P, Meeks SL.
    J Thromb Haemost; 2018 Sep 25; 16(9):1779-1788. PubMed ID: 29981270
    [Abstract] [Full Text] [Related]

  • 13. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J.
    Blood Rev; 2017 Sep 25; 31(5):339-347. PubMed ID: 28716211
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
    Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, Ciavarella N, De Rosa V, Arter A.
    Thromb Haemost; 1993 Aug 02; 70(2):270-2. PubMed ID: 8236134
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group.
    J Thromb Haemost; 2023 May 02; 21(5):1123-1134. PubMed ID: 36775768
    [Abstract] [Full Text] [Related]

  • 16. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
    Cao W, Trask AR, Bignotti AI, George LA, Doshi BS, Sabatino DE, Yada N, Zheng L, Camire RM, Zheng XL.
    J Thromb Haemost; 2023 Dec 02; 21(12):3477-3489. PubMed ID: 37726033
    [Abstract] [Full Text] [Related]

  • 17. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL, Ogiwara K, Rawley O, Brown C, Georgescu I, Hopman W, Labarque V, Male C, Thom K, Blanchette VS, Carcao MD, Lillicrap D.
    Blood; 2019 Sep 12; 134(11):880-891. PubMed ID: 31350267
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
    Ahn JW, Chang ES, Jung YJ, Kim SR, Seong BL, Ha SH.
    Arch Pharm Res; 2020 Jul 12; 43(7):714-723. PubMed ID: 32666302
    [Abstract] [Full Text] [Related]

  • 19. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
    Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D.
    Blood; 2016 Oct 20; 128(16):2007-2016. PubMed ID: 27587878
    [Abstract] [Full Text] [Related]

  • 20. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 20; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.